3-(triphenylmethyloxy)propionaldehyde | 67057-68-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 3-(triphenylmethyloxy)propionaldehyde
• 英文别名: 3-Triphenylmethoxypropionaldehyde；3-(triphenylmethoxy)-propanal；3-trityloxypropionaldehyde；3-(trityloxy)propanal；3-trityloxypropanal；β-Trityloxypropionaldehyd
• CAS: 67057-68-5
• 化学式: C₂₂H₂₀O₂
• 分子量: 316.4
• InChiKey: YVXPHNPHJLDVBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(triphenylmethyloxy)propionaldehyde 在 N-甲基吗啉 、 potassium permanganate 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 丙酮 、 乙腈 为溶剂， 反应 5.0h， 生成 N-(3-trityloxypropionyl)cysteamine
  参考文献：
  名称：

  New Antibacterial Agents Derived from the DNA Gyrase Inhibitor Cyclothialidine

  摘要：

  Cyclothialidine (1, Ro 09-1437) is a potent DNA gyrase inhibitor that was isolated from Streptomyces filipinensis NR0484 and is a member of a new family of natural products. It acts by competitively inhibiting the ATPase activity exerted by the B subunit of DNA gyrase but barely exhibits any growth inhibitory activity against intact bacterial cells, presumably due to insufficient permeation of the cytoplasmic membrane. To explore the antibacterial potential of 1, we developed a flexible synthetic route allowing for the systematic modification of its structure. From a first set of analogues, structure-activity relationships (SAR) were established for different substitution patterns, and the 14-hydroxylated, bicyclic core (X) of 1 seemed to be the structural prerequisite for DNA gyrase inhibitory activity. The variation of the lactone ring size, however, revealed that activity can be found among 11- to 16-membered lactones, and even seco-analogues were shown to maintain some enzyme inhibitory properties, thereby reducing the minimal structural requirements to a rather simple, hydroxylated benzyl sulfide (XI). On the basis of these "minimal structures" a modification program afforded a number of inhibitors that showed in vitro activity against Gram-positive bacteria. The best activities were displayed by 14-membered lactones, and representatives of this subclass exhibit excellent and broad in vitro antibacterial activity against Gram-positive pathogens, including Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, and overcome resistance against clinically used drugs. By improving the pharmacokinetic properties of the most active compounds (94, 97), in particular by lowering their lipophilic properties, we were able to identify congeners of cyclothialidine (1) that showed efficacy in vivo.

  DOI：

  10.1021/jm0310232
• 作为产物：
  描述：

  三苯基氯甲烷 在 N-甲基吲哚酮 、 四丙基高钌酸铵 、 4 A molecular sieve 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 3-(triphenylmethyloxy)propionaldehyde
  参考文献：
  名称：

  Oxidative Deprotection of 1,3-Dithiane Group Using NaClO₂and NaH₂PO₄in Aqueous Methanol

  摘要：

  在氯酸钠、磷酸二氢钠和2-甲基-2-丁烯的条件下，以3:1的甲醇-水溶液于室温下进行选择性氧化脱除1,3-二硫杂环己烷基团，产率良好。

  DOI：

  10.1055/s-2004-829558

文献信息

• Highly stereoselective kinetic resolution of α-allenic alcohols: an enzymatic approach
  作者：Wenhua Li、Zuming Lin、Long Chen、Xuechao Tian、Yan Wang、Sha-Hua Huang、Ran Hong

  DOI：10.1016/j.tetlet.2015.12.098

  日期：2016.2

  A highly efficient lipase AK-catalyzed direct kinetic resolution of a variety of α-allenic alcohols was developed. With the complementary to previous studies, the current reaction system is effective on a broad range of substituents (R1) at C(1), such as alkyl, aryl, alkenyl, and alkynyl groups. The Jones–Burgess empirical model was modified to interpret the reversed selectivity during the acetylation

  开发了一种高效脂肪酶AK催化的多种α-烯醇的直接动力学拆分方法。作为对先前研究的补充，当前的反应系统对C（1）上的广泛取代基（R 1）有效，例如烷基，芳基，烯基和炔基。修改了Jones-Burgess的经验模型，以解释仲醇乙酰化过程中逆向选择性。烯丙醇的C（2）处的甲基暗示脂肪酶AK的催化三联体中的小结构调整，代表未来定点诱变的潜在方向。
• Effect of Partially Fluorinated<i>N</i>-Alkyl-Substituted Piperidine-2-carboxamides on Pharmacologically Relevant Properties
  作者：Raffael Vorberg、Nils Trapp、Daniel Zimmerli、Björn Wagner、Holger Fischer、Nicole A. Kratochwil、Manfred Kansy、Erick M. Carreira、Klaus Müller

  DOI：10.1002/cmdc.201600325

  日期：2016.10.6

  energies, as indicated by variations in melting point temperatures. All fluorinated derivatives were found to be somewhat more readily oxidized in human liver microsomes, the rates of degradation correlating with increasing lipophilicity. Because the piperidine‐2‐carboxamide core is chiral, pairs with enantiomeric N‐alkyl groups are diastereomeric. While little response to such stereoisomerism was observed

  通过选择性地将1-3个氟原子引入n-丙基和n中，研究了N-烷基-哌啶-2-羧酰胺的药理相关特性的调节局部麻醉药罗哌卡因和左旋布比卡因的叔丁基侧链。附近氟取代基对碱的调节本质上是加和的，并且表现出随氟与碱中心之间的拓扑距离而变的指数衰减。中性哌啶衍生物的固有亲脂性显示出对连接至中性杂芳基系统的部分氟化烷基的特征响应。但是，附近的氟取代基引起的碱度降低会影响中性pH值的亲脂性，因此所有部分氟化的衍生物的亲脂性都比其未氟化的母体相似或更高。发现水溶性与亲脂性成反比，并且与晶体堆积能有很大关系，如熔点温度的变化所示。发现所有氟化衍生物在人肝微粒体中都更容易被氧化，降解速率与亲脂性增加相关。因为哌啶-2-羧酰胺核心是手性的，所以与对映异构体配对N-烷基是非对映异构的。虽然对于碱性或亲脂性几乎观察不到对这种立体异构的反应，但是对于熔点温度和氧化降解观察到更明显的变化。
• [EN] SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE SUBSTITUÉS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2017037221A1

  公开（公告）日：2017-03-09

  The invention relates to antibacterial compounds of formula (I) wherein M is one of the groups MA, MB and MC represented below wherein R1, MA, MB and MC are as defined in the specification; and to salts thereof.

  该发明涉及公式（I）中的抗菌化合物，其中M是下面所表示的MA、MB和MC中的一种基团，其中R1、MA、MB和MC如规范中所定义；以及其盐。
• DNA gyrase inhibitors and pharmaceutical preparations therefor
  申请人：Hoffmann-LaRoche Inc.

  公开号：US05294609A1

  公开（公告）日：1994-03-15

  Bicyclic derivatives of the formula ##STR1## wherein X.sup.1, X.sup.2, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7a, R.sup.7b, and R.sup.8 are as defined in the specification. These compounds are antimicrobially active.

  公式为##STR1##的双环衍生物，其中X.sup.1、X.sup.2、R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6、R.sup.7a、R.sup.7b和R.sup.8的定义如规范中所述。这些化合物具有抗微生物活性。
• [EN] 6-(BUTA-1,3-DIYN-1-YL)BENZO[D]THIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE 6-(BUTA-1,3-DIYN-1-YL)BENZO [D] THIAZOLE
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2017198647A1

  公开（公告）日：2017-11-23

  The invention relates to antibacterial compounds of formula (I) wherein the group M and R1 are as defined in the claims, and salts thereof.

  该发明涉及公式（I）中的抗菌化合物，其中基团M和R1如权利要求中所定义，并其盐。